Showing results (161-170 of 191) with videos related to

Sort By:
Pageof 20
Blood|January 25, 2002
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphomaAlessandro Rambaldi, Manuela Lazzari, Cristina Manzoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological featuresRiccardo Bomben, Michele Dal-Bo, Dania Benedetti, et al.
The Journal of Experimental Medicine|June 15, 2011
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activationGiulia Fabbri, Silvia Rasi, Davide Rossi, et al.
Haematologica|July 11, 2019
HIF-1α is over-expressed in leukemic cells from <i>TP53</i>-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemiaValentina Griggio, Candida Vitale, Maria Todaro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndromeDavide Rossi, Valeria Spina, Michaela Cerri, et al.
Genes, Chromosomes & Cancer|May 13, 2011
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemiaMichele Dal Bo, Francesca Maria Rossi, Davide Rossi, et al.
Hematological Oncology|January 30, 2024
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohortEnrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination TherapyChiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Leukemia|December 17, 2024
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirementJana Nabki, Bashar Al Deeban, Abel Mehari Sium, et al.
Hematological Oncology|July 1, 2023
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia studyFrancesco Autore, Idanna Innocenti, Gianluigi Reda, et al.
Pageof 20